Respiratory syncytial virus: Recent progress towards the discovery of effective prophylactic and therapeutic agents

Drug Discovery Today

Volumn 5, Issue 6, 2000, Pages 241-252

  Meanwell, Nicholas A ^a   Krystal, Mark ^b  

^a Department of Chemistry ^*  (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; AMITIVIR; CL 387626; DEZAGUANINE; DISULFIDE; FELVIZUMAB; GR 92938X; LIVE VACCINE; MONOCLONAL ANTIBODY; PALIVIZUMAB; PIRAZOFURIN; PYRAZOLE DERIVATIVE; RD 30028; RIBAVIRIN; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; NONHUMAN; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS ADSORPTION; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS REPLICATION;

EID: 0034212586     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01500-2     Document Type: Review

References (107)

1. Morris, J.A., Jr et al. (1956) Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Biol. Med. 92, 544-550
2. Chanock, R. et al. (1957) Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am. J. Hyg. 66, 281-290
3. Chanock, R.M. et al. (1957) Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiological aspects of infection in infants and young children. Am. J. Hyg. 66, 291-300
4. Ottolini, M.G. et al. (1997) Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery. Drugs 54, 807-884
5. Wyde, P.R. (1998) Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. 39, 63-79
6. Collins, P.L. et al. (1996) Respiratory syncytial virus. In Virology (Fields, B.N. et al. , eds), pp. 1313-1351, Raven Press
7. Byrd, L.G. et al. (1997) Animal models of respiratory syncytial virus infection. Clin. Infect. Dis. 25, 1303-1368
8. Levin, M.J. (1994) Treatment and prevention options for respiratory syncytial virus. J. Pediatr. 124, 522-527
9. Prober, C.G. et al. (1997) Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer. Pediatrics 99, 472-475
10. Kim, H.W. et al. (1974) Epidemiology of respiratory syncytial virus infection in Washington D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am. J. Epidemiol. 98, 216-225
11. Glezen, W.P. et al. (1973) Epidemiology of acute lower respiratory disease in children. New Engl. J. Med. 288, 498-505
12. Gilchrist, S. et al. (1994) National surveillance for respiratory syncytial virus, United States, 1985-1990. J. Infect. Dis. 170, 986-990
13. Halstead, D.C. et al. (1998) Continuous non-seasonal epidemic of respiratory syncytial virus infection in the southeast United States. South. Med. J. 91, 433-436
14. Hall, C.B. et al. (1981) Modes of transmission of respiratory syncytial virus. J. Pediatr. 99, 101-103
15. Hall, C.B. et al. (1976) Respiratory syncytial virus infections within families. New Engl. J. Med. 294, 414-419
16. Hall, C.B. et al. (1991) Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163, 693-698
17. Anderson, L.J. et al. (1990) Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths in infants and young children. J. Infect. Dis. 161, 640-646
18. Hall, C.B. et al. (1979) Neonatal respiratory syncytial virus infection. New Engl. J. Med. 300, 393-396
19. MacDonald, N.E. et al. (1982) Respiratory syncytial viral infection in infants with congenital heart disease. New Engl. J. Med. 307, 397-400
20. Groothius, J.R. et al. (1988) Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 82, 199-203
21. Hall, C.B. et al. (1986) Respiratory syncytial viral infection in children with compromised immune function. New Engl. J. Med. 315, 77-81
22. Corne, J.M. et al. (1997) Mechanisms of virus induced exacerbations of asthma. Thorax 52, 380-389
23. Schwarze, J. et al. (1997) Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J. Clin. Invest. 100, 226-233
24. Wang, S-Z. et al. (1998) Asthma and respiratory syncytial virus infection in infancy: is there a link? Clin. Exp. Allergy 28, 927-935
25. Stein, R.T. et al. (1999) Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354, 541-545
26. Eskola, J. et al. (1999) Respiratory viruses in acute otitis media. New Engl. J. Med. 340, 312-313
27. Chonmaitree, T. et al. (1997) Role of viruses in middle-ear disease. Ann. New York Acad. Sci. 830, 143-157
28. Heikkinen, T. et al. (1999) Prevalence of various respiratory viruses in the middle ear during acute otitis media. New Engl. J. Med. 340, 260-264
29. Englund, J.A. et al. (1988) Respiratory syncytial virus infection in immunocompromised adults. Ann. Intern. Med. 109, 203-208
30. Hertz, M.I. et al. (1989) Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine 68, 269-281
31. McColl, M.D. et al. (1998) Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant. 21, 423-425
32. Sinnott, J.T., 4th et al. (1988) Respiratory syncytial virus pneumonia in a cardiac transplant recipient. J. Infect. Dis. 158, 650-651
33. Peigue-Lafeuille, H. et al. (1990) Severe respiratory syncytial virus pneumonia in an adult renal transplant recipient: successful treatment with ribavirin. Scand. J. Infect. Dis. 22, 87-89
34. Doud, J.R. et al. (1992) Respiratory syncytial virus pneumonia in a lung transplant recipient: case report. J. Heart Lung Transplant. 11, 77-79
35. Whimbey, E. et al. (1995) Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin. Infect. Dis. 21, 376-379
36. Dowell, S.F. et al. (1996) Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174, 456-462
37. Falsey, A.R. (1998) Respiratory syncytial virus infection in older persons. Vaccine 16, 1775-1778
38. Han, L.J. et al. (1999) Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J. Infect. Dis. 179, 25-30
39. Fleming, D.M. et al. (1993) Respiratory syncytial virus or influenza? Lancet 342, 1507-1510
40. Nicholson, K.G. (1996) Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol. Infect. 116, 51-63
41. Collins, P.L. et al. (1984) Identification of a tenth mRNA of human respiratory syncytial virus and assignment of polypeptides of the 10 viral genes. J Virol. 49, 572-578
42. Johnson, P.R. et al. (1988) The fusion glycoprotein of human respiratory syncytial viruses of subgroups F and B: sequence conservation provides a structural basis for antigenic relatedness. J. Gen. Virol. 69, 2623-2628
43. Bukreyev, A. et al. (1997) Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71, 8973-8982
44. Karron, R.A. et al. (1997) Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. V. S. A. 94, 13961-13966
45. Stec, D.S. et al. (1991) Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses. Virology 183, 273-287
46. Hall, C.B. (1994) Prospects for a respiratory syncytial virus vaccine. Science 265, 1393-1394
47. Dudas, R.A. et al. (1998) Respiratory syncytial virus vaccines. Clin. Microbiol. Rev. 11, 430-439
48. Li, X. et al. (1998) Protection against respiratory syncytial virus infection by DNA immunization. J. Exp. Med. 188, 681-688
49. Collins, P.L. et al. (1999) Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv. Virus Res. 54, 423-451
50. Whitehead, S.S. et al. (1999) Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J. Virol. 73, 871-877
51. Whitehead, S.S. et al. (1999) Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73, 3438-3442
52. Ball, L.A. et al. (1999) Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol. 73, 4705-4712
53. Tebbey, P.W. et al. (1999) A novel and effective immunization strategy for respiratory syncytial virus. Viral Immunol. 12, 41-45
54. Hemming, V.G. et al. (1995) Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8, 22-33
55. Weltzin, R. (1998) The therapeutic potential of monoclonal antibodies against respiratory syncytial virus. Expert Opin. Invest. Drugs 7, 1271-1283
56. Groothuis, J.R. et al. (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The respiratory syncytial virus immune globulin study group. New Engl. J. Med. 329, 1524-1530
57. Rodriguez, W.J. et al. (1997) Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: the respiratory syncytial virus immune globulin study group. Pediatrics 99, 454-461
58. Rodriguez, W.J. et al. (1997) Respiratory syncytial virus (RSV) immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 100, 937-942
59. PREVENT Study Group (1997) Reduction of respiratory syncytial virus hospitalization among premature infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99, 93-99
60. Simoes, E.A. et al. (1998) Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The cardiac study group. J. Pediatr. 133, 492-499
61. Hay, J.W. et al. (1996) Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am. J. Man. Care 2, 851-861
62. Meissner, H.C. et al. (1999) Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209703) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob. Agents Chemother. 43, 1183-1188
63. Johnson, S. et al. (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215-1224
64. Impact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537
65. Malley, R. et al. (1998) Reduction of respiratory syncytial virus (RSV) in trachea! aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178, 1555-1561
66. Meissner, H.C. et al. (1999) Immunoprophylaxis with Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr. Infect. Dis. J. 18, 223-231
67. Johnson, S. et al. (1999) Direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. J. Infect. Dis. 180, 35-40
68. Ottolini, M.G. et al. (1999) Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant. 24, 41-45
69. De Clercq, E. (1996) Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections. Int. J. Antimicrob. Agents 7, 193-202
70. Shigeta, S. (1998) Approaches to antiviral chemotherapy for acute respiratory infections. Antiviral Chem. Chemother. 9, 93-107
71. Prince, G.A. (1999) Respiratory syncytial virus antiviral agents. Expert Opin. Ther. Pat. 9, 753-762
72. Barnard, D.L. et al. (1997) Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses. Antiviral Chem. Chemother. 8, 223-233
73. Gilbert, B.E. et al. (1986) Biochemistry and clinical application of ribavirin. Antimicrob. Agents Chemother. 30, 201-205
74. Simoes, E.A.F. (1997) Respiratory syncytial virus infection: pathogenesis, treatment and prevention. Curr. Opin. Infect. Dis. 10, 213-220
75. Patterson, J.L. et al. (1990) Molecular mechanisms of action of ribavirin. Rev. Infect. Dis. 12, 1139-1146
76. De Clercq, E. et al. (1991) Antiviral activities of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35, 679-684
77. Hruska, J.F. et al. (1980) Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob. Agents Chemother. 17, 770-5
78. Hruska, J.F. et al. (1982) In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob. Agents Chemother. 21, 125-130
79. Shigeta, S. et al. (1992) Antiviral activities of ribavirin, 5-ethynyl-1-β-Dribofuranosylimidazole-4-carboxamide and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob. Agents Chemother. 36, 435-439
80. Wang, W. et al. (1996) Inactivation of inosine 5′-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide 5′-monophosphate. Biochemistry 35, 95-101
81. Kawana, F. et al. (1985) Inhibitory effects of several antiviral compounds on the replication of respiratory syncytial virus in vitro. Antiviral Res. 8, 83-88
82. Woods, J.M. et al. (1994) Inhibition of respiratory syncytial virus replication in vitro by a pyrazole dicarboxamide analogue of ribavirin. Antiviral Chem. Chemother. 5, 340-343
83. Wyde, P.R. et al. (1990) Toxicity and antiviral activity of LY-253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res. 14, 237-247
84. Barnard, D.L. et al. (1997) Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antiviral Res. 34, 27-37
85. Rhule, J.T. et al. (1998) Polyoxometalates in medicine. Chem. Rev. 98, 327-357
86. Wild, C. et al. (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U. S. A. 89, 10537-10541
87. Furata, R.A. et al. (1998) Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5, 276-279
88. Lambert, D.M. et al. (1996) Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl. Acad. Sci. U. S. A. 93, 2186-2191
89. Kilby, J.M. et al. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302-1307
90. Johnson, MR. et al. (Trimeris) (1998) Benzanthrone compounds and antiviral uses thereof. WO 98/39287
91. Wyde, P.R. et al. (1998) CL-387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Res. 38, 312
92. Ding, W. et al. (1998) Novel and specific respiratory syncytial virus inhibitors that target virus fusion. J. Med. Chem. 41, 2671-2675
93. Tidwell, R.R. et al. (1978) Diarylamidine derivatives with one or both aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases. J. Med. Chem. 21, 613-623
94. Tidwell, R.R. et al. (1983) Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin and trypsin. J. Med. Chem. 26, 294-298
95. Tidwell, R.R et al. (1984) Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amidino-2-benzimidazolyl)methane. Antimicrob. Agents Chemother. 26, 591-593
96. Katz, B.A. et al. (1998) Design of potent selective zinc-mediated serine protease inhibitors. Nature 351, 608-612
97. Watanabe, W. et al. (1998) Novel anti-respiratory syncytial (RS) viral compounds: benzodithiin derivatives. Biochem. Biophys. Res. Commun. 249, 922-926
98. Sudo, K. et al. (1999) Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Antimicrob. Agents Chemother. 43, 752-757
99. Sudo, K. et al. (1998) Mechanism of specific inhibition on respiratory syncytial virus replication by benzodithiin compound, RD3-0028. Antiviral Res. 37, A89
100. Nitz, T.J. et al. (Viropharma) (1999) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases. WO 99/38508
101. Bishofberger, N. et al. (1992) Antisense approaches to antiviral agents. Semin. Virol. 3, 57-66
102. Jairath, S. et al. (1997) Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res. 33, 201-213
103. Torrence, P.F. et al. (1994) Development of 2′,5′-oligonucleotides as potential therapeutic agents. Curr. Med. Chem. 1, 176-191
104. Torrence, P.F. et al. (1993) Targeting RNA for degradation with a (2′,5′)-oligoadenylate-antisense chimera. Proc. Natl. Acad. Sci. U. S. A. 90, 1300-1304
105. Xiao, W. et al. (1997) Inhibition of respiratory syncytial virus by double termini-protected 2-5A antisense chimeras. Nucleosides Nucleotides 16, 1735-1738
106. Cirino, N.M. et al. (1997) Targeting RNA decay with 2′,5′ oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proc. Natl. Acad. Sci. U. S. A. 94, 1937-1942
107. Player, M.R. et al. (1998) Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc. Natl. Acad. Sci. U. S. A. 95, 8874-8879